Inovio Adds Pre-Funded Warrants to Underwritten Offering Days After First VOCERYQ Approval
INO has more than doubled off its 52-week low of $0.563.
Summary
Inovio's free writing prospectus adds pre-funded warrants to the underwritten common stock offering it launched November 5, 2026, widening the buyer base for a raise meant to fund the VOCERYQ launch. Pricing and share count remain blank, so dilution is not yet quantifiable.
Key Events · Financing and Capital Events · INO
-
Pre-Funded Warrants Added to Offering
The free writing prospectus supplements the November 5, 2026 preliminary prospectus to add pre-funded warrants, in lieu of common stock for investors who so choose, at an exercise price of $0.001 per share.
-
Warrant Terms and Ownership Blocker
Each pre-funded warrant costs the common stock public offering price minus $0.001, is exercisable immediately, never expires until fully exercised, and carries a 9.99% ownership cap that a holder can raise to 19.99% with 61 days' notice.
-
Underwriters' 15% Option
Jefferies and Piper Sandler hold a 30-day option to buy additional shares equal to 15% of the total shares offered plus the shares underlying the pre-funded warrants.
-
Proceeds for VOCERYQ Launch
Net proceeds are intended primarily to fund the commercial launch of VOCERYQ, for clinical pipeline development and general corporate purposes; the dollar amount is left blank pending pricing.
Analysis · INO · Life Sciences
Inovio is amending the structure of the underwritten stock sale it launched on November 5, adding pre-funded warrants at a $0.001 strike so that buyers who cannot hold more common stock (or want to defer settlement) can still participate. The economics are essentially the same as buying the common — the warrant costs the share price minus a tenth of a cent — so this is not extra money raised, it is a wider buyer base for the same deal. Proceeds are earmarked for the commercial launch of VOCERYQ, Inovio's first approved product, which the FDA cleared on October 30, 2026. Against that backdrop the raise is a survival-and-execution necessity: the last 10-Q carried a going concern warning with cash runway only into late Q1 2027, and the company disclosed roughly $48.4 million of quarter-end cash on November 5. The offering terms — share count, price, and net proceeds — are still blank in this document, so the actual dilution cannot yet be sized; the final 424B5 pricing will settle that.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.